Skip to main content
SpringerLink
Log in

90Y-DOTATATE/Octreotate-Lu177-DOTA-Tyr-3

Thrombocytopenia and hyperbilirubinaemia: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kong G, et al. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 44: 476-489, No. 3, Mar 2017. Available from: URL: http://doi.org/10.1007/s00259-016-3527-x - Australia

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

90Y-DOTATATE/Octreotate-Lu177-DOTA-Tyr-3. Reactions Weekly 1641, 13 (2017). https://doi.org/10.1007/s40278-017-26927-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-26927-4

Search

Navigation